Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Sturm, Ruger & Co. reported net sales of $147.6 million for the third quarter of 2026, an increase from $126.8 million in the prior year period. Net income improved significantly to $5.8 million compared to $1.6 million in Q3 2025, driven by higher firearms sales and improved gross margins. The company maintained a strong balance sheet with $101.4 million in cash and short-term investments.
KLX Energy Services Holdings, Inc. appointed Franklin S. Edmonds, Jr. and E. Dirk Hallen to its Board of Directors as independent directors. The appointments were made pursuant to a Rights Offering Backstop Agreement, with Edmonds designated by Cross Ocean Partners Management LP and Hallen designated by Whitebox Advisors LLC.
Valuence Merger Corp. I has extended the deadline to complete its initial business combination from November 3, 2026, to December 3, 2026. This represents the seventh of ten available one-month extensions, and the company deposited $13,897.14 into its trust account to effect the extension.
Karat Packaging Inc. announced that its Board of Directors has declared a regular quarterly cash dividend of $0.47 per share on its common stock. The dividend is payable on November 27, 2026, to stockholders of record as of November 19, 2026.
Nordicus Partners Corp closed a private offering of 40,000 restricted shares of common stock to two private investors. The shares were issued at a price of $2.00 per share, resulting in total proceeds of $80,000. The transaction was conducted as a private placement exempt from registration under Section 4(a)(2) and Regulation D.
Social Commerce Partners Corp reported net income of $2,137,374 for the nine months ended September 30, 2026, primarily driven by $2,703,987 in interest earned on marketable securities held in its Trust Account. As a shell company, it has not yet generated operating revenue and is currently seeking a target for its initial Business Combination.
For the nine months ended September 30, 2026, Zimmer Biomet reported net sales of $6,326.6 million, a 5.7% increase over the prior year, and net earnings of $630.9 million. The company experienced higher selling, general, and administrative expenses but saw an improvement in operating profit from $943.6 million to $1,006.8 million year-over-year.
Warrior Met Coal reported third quarter 2026 results with net income of $49.3 million and a 48% increase in sales volumes driven by the Blue Creek mine. The company generated $166.0 million in operating cash flow and declared a $2.00 per-share special dividend.
Term
Q3 2026
“We delivered strong sales volumes in the third quarter as Blue Creek continued to expand our production base and strengthen our cash-generating capacity.”
Walt Scheller, CEO of Warrior
“The special dividend announced this quarter represents an important milestone for Warrior and demonstrates how quickly Blue Creek is beginning to translate into value for our stockholders.”
Lightbridge Corporation reported a net loss of $20.4 million for the nine months ended September 30, 2026, compared to $12.4 million in the prior year, driven by increased R&D and G&A expenses. The company maintained a strong liquidity position with $236.7 million in cash and cash equivalents, bolstered by $48.9 million in net proceeds from registered stock offerings during the period.
Old Dominion Freight Line reported a significant increase in net income to $343.7 million for the third quarter of 2026, up from $270.9 million in the prior year, driven by a 13.1% growth in revenue. The company maintained a strong liquidity position with cash and cash equivalents increasing to $466.2 million as of September 30, 2026.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing product candidates such as claseprubart, DNTH212, and DNTH312. As of November 2, 2026, the company reported 56,312,712 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
Zomedica Corp. reported net revenue of $9.9 million for the third quarter of 2026, a 22% increase compared to the same period in 2025. The company significantly reduced its net loss to $11.5 million for the first nine months of 2026, down from a $77.3 million loss in the prior year which was impacted by a large impairment expense.
Adeia Inc. reported revenue of $80.2 million for the third quarter of 2026, a decrease from $87.3 million in the prior year period. Despite the revenue decline, the company maintained profitability with a net income of $2.3 million for the quarter and $42.4 million for the nine months ended September 30, 2026.
Personalis reported Q3 2026 total revenue of $25.6 million, a significant increase from $14.5 million in the prior year, driven by growth in clinical test volume and population sequencing. The company ended the quarter with $190.6 million in cash and noted its pending merger with Tempus AI. Due to the pending acquisition, the company is no longer providing forward-looking financial guidance.
“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners.”
Personalis, Inc. has entered into a definitive merger agreement to be acquired by Tempus AI, Inc. The company continues to report a history of losses and maintains significant customer concentration with Moderna, the VA MVP, and Merck while focusing on its partner-centric strategy for cancer testing services.
GRAIL reported third quarter 2026 financial results, highlighted by a 14% year-over-year increase in Galleri test revenue to $37.3 million and a favorable FDA Advisory Committee vote for the Galleri multi-cancer early detection test. The company reported a net loss of $103.6 million for the quarter and maintains a cash position of $788.7 million as it anticipates an FDA approval decision by early Q1 2027.
“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee. This achievement strengthens the foundation for Galleri as we continue on our path towards potential regulatory approval, broader access and reimbursement. We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction.”
Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL
Solstice Advanced Materials Inc. reported net sales of $1,046 million for the third quarter of 2026, up from $969 million in the prior year period. Net income attributable to the company improved to $80 million compared to a net loss of $35 million in Q3 2025, driven largely by a significant reduction in income tax expense.
Diamondback Energy, Inc. is a large accelerated filer reporting for the quarter ended September 30, 2026, with 279,167,841 shares of common stock outstanding as of October 30, 2026. The filing outlines the company's financial position, including its portfolio of senior notes and its consolidated subsidiary structure involving Viper Energy, Inc.
OnKure Therapeutics reported a net loss of $48.3 million for the nine months ended September 30, 2026, compared to $46.0 million in the prior year period. The company significantly strengthened its balance sheet, ending the quarter with $151.4 million in cash and cash equivalents following the issuance of Class A common stock.
Purple Innovation reported Q3 2026 net revenue of $96.5 million, an 18.7% decrease year-over-year, primarily due to lower wholesale performance. Despite the revenue decline, the company achieved its third consecutive quarter of positive operating cash flow and significantly narrowed its GAAP net loss to $1.4 million.
Term
Q3 2026
“Third quarter performance was mixed as we continued to navigate a challenging mattress environment. We were encouraged by improving momentum in our e-commerce business as the quarter progressed, supported by stronger conversion rates on Purple.com, and we opened two new showrooms during the quarter, bringing our network to 57 stores.”
Rob DeMartini, CEO of Purple Innovation
“We have taken steps to improve our cost structure, and are consistently generating cash, with positive operating cash flow for the third consecutive quarter. At the same time, we are actively preparing for a significant product refresh planned for early 2027, including new Essentials and Hybrid collections representing almost 90% of our mattress unit volume.”
CoreCivic reported third quarter 2026 financial results, highlighted by a $1.8 billion gain on the sale of four detention facilities for $2.2 billion in gross proceeds. The company used proceeds to repay over $700 million in debt and enter into a $500 million accelerated share repurchase agreement, while the Board authorized an additional $500 million for future stock buybacks.
“We delivered strong financial results in a very active quarter, driven by increased demand for our services from U.S. Immigration and Customs Enforcement (ICE), including higher utilization of recently activated facilities, as well as the contribution from our acquisition of Clinical Solutions Pharmacy earlier this year.”
Lucibeth Mayberry, CoreCivic’s President and Chief Executive Officer
“The sale of four detention facilities to the federal government during the third quarter generated total gross proceeds of $2.2 billion and a $1.8 billion aggregate gain on sale of real estate assets. We used a portion of the net proceeds after income taxes and transaction costs, amounting to $1.6 billion, to repay over $700.0 million of debt and to make a payment of $500.0 million under an ASR.”
Lucibeth Mayberry, CoreCivic’s President and Chief Executive Officer
John T. Hall, CEO, sold 2,900 shares of Intapp, Inc. at $43.31 to $46.11 a share (average $45.03) in 4 transactions, worth $131K in total on Nov 2, 2026. Shares held after the trade: 5,814,808 (-0.0%).
LCNB Corp. reported net income of $7.3 million for the third quarter of 2026, up from $6.9 million in the prior year period, driven by higher net interest income. Total assets grew to $2.28 billion as of September 30, 2026, while the company maintained a strong capital position with total shareholders' equity of $282.2 million.
Onterris reported Q3 2026 financial results with revenue of $203.0 million and net income of $9.0 million, while reiterating its full-year 2026 guidance. The company also announced the completion of three small tuck-in acquisitions in the second half of 2026 and provided an update on its ongoing board-led strategic review process.
Term
Q3 2026
“Our third-quarter results demonstrate meaningful progress against our objectives for the year. Compared to prior year, we delivered higher Adjusted EBITDA, record consolidated margins and stronger cash generation despite lower reported revenue due to the normalization of episodic environmental emergency response-related recovery services. Strong growth in core consulting and water treatment services reinforces the underlying demand for our solutions, while improved project execution, favorable business mix and cost discipline are strengthening the profitability of our platform.”
Vijay Manthripragada, President and Chief Executive Officer
Net Lease Office Properties reported a net loss of $0.6 million for the third quarter of 2026, a significant improvement from the $64.1 million loss in the prior year period. The company continues its strategy of asset disposition, resulting in a net gain on sale of real estate of $38.6 million for the nine months ended September 30, 2026.
Vertex, Inc. reported third quarter 2026 total revenues of $213.3 million, an 11% increase year-over-year, driven by 20.4% growth in cloud revenues. The company achieved an Adjusted EBITDA of $64.8 million and raised its full-year 2026 revenue guidance to a range of $828.9 million to $830.9 million.
Term
Q3 2026
“The third quarter was a strong quarter for Vertex and, more importantly, clear evidence that we are delivering on our commitments to investors. We have stabilized the core business, strengthened our financial profile, and built a more efficient operating model, while seeing encouraging improvement in key growth indicators.”
Christopher Young, President and Chief Executive Officer
“Our third quarter results reflect continued progress against the priorities we established earlier this year, with solid revenue growth and a strengthened financial profile.”
Stellar V Capital Corp. held its annual general meeting on October 29, 2026, where shareholders approved an extension of the deadline to complete a business combination from October 31, 2026, to July 31, 2027. Shareholders also voted to re-elect directors and ratify the company's independent auditors.
Viasat adopted the Viasat Value Creation Incentive Program (V-CIP), a long-term performance-based equity plan designed to grant up to 2.8 million PSUs to key contributors, including CEO Mark Dankberg. The awards are tied to rigorous stock price hurdles ranging from $150 to $300 (2x to 4x the current price) and require service through December 31, 2030, to vest.
Grand Canyon Education, Inc. reported its third quarter 2026 financial results, showing a 2.4% increase in service revenue to $267.3 million. Operating income rose significantly to $51.5 million, driven by a 5.2% increase in total university partner enrollments to 145,270.
Revolution Medicines reported financial results for the third quarter of 2026, highlighted by the U.S. commercial launch of RASONQUE (daraxonrasib) for metastatic pancreatic cancer. The product generated $197.6 million in net revenue during its first five weeks on the market, with over 5,000 unique patients treated. The company also received a positive CHMP opinion for the drug in the European Union.
Term
Q3 2026
“The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union.”
Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines